Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22184082 | 0.84 | — | — | |
| SCHEMBL23948568 | 0.84 | PSMB8 (0.33) | PSMB8PSMB5 | |
| SCHEMBL25815449 | 0.83 | — | — | |
| SCHEMBL20569206 | 0.82 | ADRA2A (0.34) | TSHR | |
| SCHEMBL14948533 | 0.79 | TSHR (0.43) | TSHR | |
| SCHEMBL14644916 | 0.78 | PSMB8 (0.33) | PSMB8PSMB5TSHR | |
| SCHEMBL43576 | 0.76 | PSMB8 (0.35) | PSMB8PSMB5TSHR | |
| SCHEMBL20569208 | 0.76 | CYP2C19 (0.37) | TSHR | |
| SCHEMBL141048 | 0.75 | ADRA2A (0.36) | PSMB8PSMB5 | |
| SCHEMBL31522720 | 0.75 | PSMB8 (0.34) | PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152728-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-15 | — | — | US | disclosed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| EP-4223319-A2 | METHOD AND MOLECULES | MedImmune, LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4223319-A2 | METHOD AND MOLECULES | MedImmune, LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3630732-B1 | METHOD AND MOLECULES | MEDIMMUNE LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3630732-B1 | METHOD AND MOLECULES | MEDIMMUNE LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20200206359-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152728-A1 | Method And Molecules | PAICS, EPCAM, SQLE | PSMB8 2537/4885PSMB5 2922/4885TSHR 1084/4885 |
| US-20200206359-A1 | Method And Molecules | PAICS, EPCAM, SQLE | PSMB8 2537/4885PSMB5 2922/4885TSHR 1084/4885 |
| US-20230321267-A1 | Method And Molecules | PAICS, EPCAM, SQLE | PSMB8 2537/4885PSMB5 2922/4885TSHR 1084/4885 |
| US-11759526-B2 | Method and molecules | PAICS, EPCAM, SQLE | PSMB8 2537/4885PSMB5 2922/4885TSHR 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.